Katakura Industries Co.,Ltd.
3001・Standard Market・Textiles & Apparels
Business
Katakura Industries is a long-established company founded in 1873 that has pursued business diversification while leveraging the historical assets it accumulated as a silk manufacturer. It currently comprises five segments: "Real Estate Business," "Pharmaceutical Business," "Machinery-Related Business," "Textile Business," and "Other." In the Real Estate Business, the company operates commercial facilities and leasing operations centered on "Cocoon City" in Saitama Shintoshin. In the Pharmaceutical Business, its subsidiary Toa Eiyo manufactures and sells prescription pharmaceuticals focused mainly on the cardiovascular field. In the Machinery-Related Business, its subsidiary Nippon Kikai Kogyo manufactures and sells fire trucks, while the Textile Business operates along two axes: functional fibers (heat-resistant and water-soluble) and practical apparel. Consolidated net sales for FY2025 (ending December 2025) were ¥40,652 million.
Business Model
The core of earnings is the commercial facility and rental real estate business, including Cocoon City, which leverages the company-owned land in Saitama Shintoshin, generating stable rental income. Building on this foundation, the group diversifies its revenue sources by operating in pharmaceutical manufacturing and sales (Toa Eiyo), made-to-order manufacturing and sales of fire trucks (Nippon Kikai Kogyo), and manufacturing and sales of functional textiles and apparel (Nichibi, Ograngeh Japan). Through its group finance system, the company enhances capital efficiency, combining operating cash flow with financial institution borrowings to fund capital expenditures and development.
Company Strengths
The fair value of rental properties stands at ¥136,398 million, significantly diverging from the book value of ¥26,535 million, resulting in unrealized gains of approximately ¥109,863 million. The high-quality real estate portfolio, centered on company-owned land in Saitama Shintoshin, underpins both financial stability and potential asset value.
In FY2025 (ending December 2025), the equity ratio reached 63.8% (up 2.7 points year on year), the interest coverage ratio reached 65.7x (up from 57.2x in the previous period), and the ratio of cash flow to interest-bearing debt improved to 1.1 years (down from 1.9 years), reflecting a marked improvement in financial soundness. Operating cash flow increased 46% year on year to ¥8,244 million.
In FY2025 (ending December 2025), the Real Estate Business recorded operating profit of ¥4,395 million, maintaining a high operating margin of 37.6%. Strategic tenant renewals at Cocoon City drove sales up 5.0% year on year to ¥11,699 million, making the segment a core profit driver that accounted for over 75% of the group's overall operating profit (¥5,855 million).
ENVALITH's Perspective
Performance Trend
Sales over the past five fiscal years were ¥37,627 million (FY2021) → ¥34,274 million (FY2022) → ¥39,972 million (FY2023) → ¥39,424 million (FY2024) → ¥40,652 million (FY2025), trending roughly flat. Operating profit recovered from a trough of ¥1,369 million in FY2022 to a sharply improved ¥5,855 million in FY2025. In Q1 of FY2026 (ending December 2026), sales were ¥11,157 million (down 0.9% year on year), a slight decline, but a lower cost-of-sales ratio (63.7% this period versus 65.9% in the same period last year) and reduced SG&A expenses (from ¥2,142 million to ¥2,006 million) drove operating profit to ¥2,040 million (up 20.3% year on year) and net profit attributable to owners of the parent to ¥1,777 million (up 31.9% year on year), a substantial increase in profit. Comprehensive income surged to ¥4,772 million from ¥155 million in the same period last year, driven by expanded valuation gains on investment securities (an external factor reflecting the rise in stock market conditions). The full-year forecast maintains a conservative outlook, with sales of ¥41,100 million (up 1.1% year on year) and operating profit of ¥5,500 million (down 6.1% year on year).
Growth Strategy
Pursuing medium- to long-term growth through three pillars: strengthening the real estate foundation, expanding functional fiber production, and reforming the pharmaceutical business structure
Continuing strategic tenant renewals and facility environment improvements on company-owned land in Saitama-Shintoshin to enhance area value. Promoting a rental condominium development plan around Cocoon City to further expand the revenue base of the real estate business. Real estate segment sales in Q1 of FY2026 (ending December 2026) grew steadily to ¥2,944 million (up 7.2% year on year).
Promoting overseas market development based on demand trends, centered on heat-resistant fibers, while strengthening the production system through the anticipated commencement of operation of the No. 4 firing furnace in the second half of 2026. Fiber segment operating profit in Q1 of FY2026 (ending December 2026) improved significantly to ¥275 million (up 58.2% year on year), confirming robust sales of functional fibers.
Continuing to embed the effects of organizational reform, promote sales alliances with other companies, and strengthen the product lineup through generic drug launches, additional formulations, and expanded indications. Tolvaptan OD Tablets 3.75mg "TE," launched in December 2025, contributed to a significant improvement in pharmaceutical segment operating profit, which rose to ¥125 million (up 458.5% year on year) in Q1 of FY2026 (ending December 2026). Also advancing a broad range of pharmaceutical development beyond the cardiovascular field.
Continuing to improve productivity through specification consolidation and appropriate pricing, centered on the fire truck business. Enhancing business stability and profitability by expanding the product lineup through collaboration with overseas manufacturers (such as MAGIRUS GmbH). Normalization from the timing lag caused by the chassis model change impact is a challenge for the second half of 2026 and beyond.
Last updated: July 17, 2026